|
HYBIO PHARMACEUTICAL CO., LTD.
|
Indications:
- Improvement of glycemic control in adults with type 2 diabetes mellitus.
- Treatment of adults with obesity or overweight, having weight-related comorbidities or complications.
Mechanism of Action: Liraglutide mimics the action of the endogenous hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, delays gastric emptying, and reduces appetite and food intake.
Pharmacokinetics:
- Absorption: Subcutaneously administered, with peak plasma concentrations achieved in 11 hours.
- Distribution: Vd approximates 20-25 L.
- Metabolism: Metabolized via endogenous pathways similarly to large proteins without a specific organ as a major route of elimination.
- Excretion: Mainly through feces.
Form: Liraglutide API is typically found as a clear and colorless solution or as a white lyophilized powder. |
Send Inquiry
|
|
Yifan Pharmaceutical Co., Ltd
|
Liraglutide API (CAS No. 204656-20-2) is a glucagon-like peptide-1 (GLP-1) analog modified with a C-16 fatty acid side chain to prolong half-life. It comprises 31 amino acids and is produced via recombinant DNA technology using Saccharomyces cerevisiae (baker’s yeast).
Key Features:
• High Purity: Complies with pharmacopeial standards (CP/EP), ensuring minimal impurities.
• Bioactivity: Acts as a GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion, suppressing glucagon, and delaying gastric emptying.
• Applications: Treats type 2 diabetes mellitus, obesity, and reduces cardiovascular risk in high-risk patients.
• Quality Assurance: Manufactured under cGMP; rigorously tested for identity, potency, sterility, endotoxins, and residual solvents.
Storage: Stable at 2–8°C; protect from light and freezing. |
Send Inquiry
|
Pharma Sources Insight January 2025
